Novo Nordisk Presents Post Hoc Analysis Of REDEFINE 1 Showing 10.9 Mmhg Reduction In Systolic Blood Pressure With Investigational CagriSema, At ObesityWeek

Author: Benzinga Newsdesk | November 06, 2025 02:37pm

• A post hoc analysis of REDEFINE 1 demonstrated a 10.9 mmHg reduction in systolic blood pressure with investigational CagriSema (2.4 mg/2.4 mg), allowing 40% of people on blood pressure medications to reduce or stop their medication1
• CagriSema treatment demonstrated a nearly 70% reduction in a key inflammatory marker associated with increased cardiovascular risk2
• Data showed that fewer people on CagriSema were at intermediate-to-high risk of developing atherosclerotic cardiovascular disease (ASCVD) within the next 10 years3

PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Nov. 6, 2025 /PRNewswire/ -- At ObesityWeek® (November 4-7 in Atlanta, GA), Novo Nordisk presented new post hoc analyses from the phase 3 REDEFINE 1 trial evaluating CagriSema, an investigational injectable combination treatment for adults with overweight or obesity, and its effects on well-known cardiovascular (CV) risk factors, including hypertension and systemic inflammation.1-3 The results from the post hoc analysis of REDEFINE 1, exploring the CV risk reduction potential of investigational CagriSema, were also simultaneously published in Hypertension.

Posted In: NVO